Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Increase in Short Interest

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 24,900 shares, an increase of 6.4% from the February 13th total of 23,400 shares. Based on an average daily trading volume, of 5,800 shares, the short-interest ratio is currently 4.3 days. Currently, 0.5% of the company’s stock are sold short.

Anebulo Pharmaceuticals Stock Down 6.0 %

Shares of ANEB stock opened at $2.51 on Thursday. The company has a 50 day moving average of $2.89 and a 200-day moving average of $2.83. Anebulo Pharmaceuticals has a 12-month low of $1.77 and a 12-month high of $7.73. The firm has a market cap of $64.34 million, a P/E ratio of -5.70 and a beta of -1.43.

Analysts Set New Price Targets

Separately, Benchmark decreased their price objective on shares of Anebulo Pharmaceuticals from $10.00 to $8.00 and set a “speculative buy” rating for the company in a research note on Tuesday, February 14th.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Nantahala Capital Management LLC purchased a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 511,073 shares of the company’s stock, valued at approximately $1,431,000. Nantahala Capital Management LLC owned about 1.99% of Anebulo Pharmaceuticals as of its most recent SEC filing. Institutional investors own 26.70% of the company’s stock.

Anebulo Pharmaceuticals Company Profile

(Get Rating)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.